Hosted on MSN2d
Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema
The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.
Their arms, legs and throats start randomly swelling. Then scientists ‘engineered’ a precision treatment
The swelling started with almost no warning, then seven-year-old Fiona Wardman’s hand ballooned like a rubber glove hooked to ...
Zacks.com on MSN2d
NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate
Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...
Healio10d
Lanadelumab increases attack-free rates in hereditary angioedema patients
Lanadelumab effectively improved attack-free rates of type I and II hereditary angioedema patients, according to a study ...
Nasdaq3d
Intellia Therapeutics Doses First Patient in Global Phase 3 Study of NTLA-2002 for Hereditary Angioedema Treatment
Intellia Therapeutics, Inc. announced the dosing of the first patient in the global Phase 3 study for NTLA-2002, a CRISPR-based therapy aimed at treating hereditary angioedema (HAE). This ...
Intellia Therapeutics announces first patient dosed in Phase 3 NTLA-2002
Intellia Therapeutics (NTLA) announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of ...
WAtoday2d
Their arms, legs and throats start randomly swelling. Then scientists ‘engineered’ a precision treatment
“We had no idea what it was,” says Wardman. She was terrified. The swollen hand of a patient with hereditary angioedema.Credit: HAE Australasia / Supplied As she hit puberty, the attacks ...